No Detail Found!

Clinical trial evaluating efficacy and safety of pemetrexed based chemotherapy regimen versus ramucirumab plus erlotinib in Chinese patients with lung cancer: A preliminary investigation

Author(s)
Qin Mei Department of Medical Oncology, The First People's Hospital of Wenling,Wenling, Zhejiang,China
Lingjun Ye Department of Medical Oncology, The First People's Hospital of Wenling,Wenling, Zhejiang,China
Chunyou Chen Department of Neurology, The First People's Hospital of Wenling,Wenling, Zhejiang,China
Hao Lin Department of Medical Oncology, The First People's Hospital of Wenling,Wenling, Zhejiang,China
Abstract
To carry out a preliminary clinical trial to compare the effectiveness and safety of pemetrexed based chemotherapy regimen in combination of cisplatin versus ramucirumab plus erlotinib in Chinese patients with metastatic non-small-cell lung cancer (NSCLC). Patients with confirmed diagnosis of NSCLC were randomly (1:1 ratio) grouped and treated intravenously with a mixture of pemetrexed (500 mg/m2) and cisplatin (75 mg/m2) plus Best Supportive Care (BSC), or ramucirumab (8 mg/kg) intravenously (IV) + erlotinib 25 mg/day. Overall survival (OS), overall response rate (ORR), progression free survival (PFS), and the safety were assessed. Pemetrexed based chemotherapy regimen in combination of cisplatin showed significantly higher OS (14.4 months vs. 10.47 months, p<0.05) and PFS (9.5 months vs. 5.1 months) than ramucirumab plus erlotinib. Objective response was also favorable in the patients treated with pemetrexed based chemotherapy regimen, when compared with those given ramucirumab plus erlotinib. Pemetrexed based chemotherapy regimen found more effective to ramucirumab plus erlotinib in improving OS, PFS and ORR, and it offers greater clinical benefits than ramucirumab plus erlotinib in Chinese NSCLC patients. Pemetrexed based chemotherapy regimen in combination of cisplatin appears to be better choice of drug for the treatment of Chinese patients with advanced stage of lung cancer.
Publication Details
Page(s) 2379-2384
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 33, Issue: S5, Year: 2020

Request the full text from PASTIC

Keywords
Pemetrexed based chemotherapy regimen, Lung Cancer, Erlotinib, ramucirumab, Cisplatin
References
Aberle DR,Adams AM,Berg CD,Black WC,Clapp JD,Fagerstrom RM,Gareen IF,Gatsonis C,Marcus PM,Sicks JD .2011 .National Lung Screening Trial Research Team reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med, 365(5) : 395-409.
Andrew X Zhu ,Clin .2018 .REACH-2: A randomized, doubleblind, placebo-controlled phase 3 trial of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. Gastrointestinal (non-colorectal) Cancer. , 36(15) : 4003-4003.
Barrera L,Montes-Servín E,Barrera A,Ramírez-Tirado LA,Salinas-Parra F,Bañales-Méndez JL,SandovalRíos M,Arrieta O M .2015 .Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis. , 26(2) : 428-435.
Chang CH,Hsiao CF,Yeh YM,Chang GC,Tsai YH,Chen YM,Huang MS,Chen HL,Li YJ,Yang PC,Chen CJ .2013 .Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int. J. Cancer., 132(9) : 1977-1985.
Escudier B,Eisen T,Stadler WM .2007 .Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med, 356(2) : 125-134.
Franco F and Provencio M,Garcia-CR F,Maurel J,Ayoub JP,Moore MJ,Cervantes A .2014 .An open-label phase II trial evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. Oncologist., 19(4) : 350-51.
Gould MK .2014 .Clinical practice Lung-cancer screening with low-dose computed tomography. N Engl J Med, 371(19) : 1813-1820.
Han BH,Yang LL,Wang X,Yao LD .2018 .Efficacy of pemetrexed-based regimens in advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: A systematic review. Onco Targets Ther., 11 : 2121-2129.
Hellmann MD .2015 .Preliminary safety, pharmacokinetics and efficacy of regorafenib, cisplatin, and pemetrexed in patients with advanced non-squamous non-small cell lung cancers. Clin. Lung Cancer, 16(6) : 514-522.
Hoffman PC,Mauer AM,Vokes EE .2000 .Lung cancer. , 355(9202) : 479-485.
Hu X .2018 .The anti-tumor effect of regorafenib in lung squamous cell carcinoma in vitro. Biochem. Biophys. Res. Commun., 503(2) : 1123-1129.
Morabito A .2018 .Second-line treatment for advanced NSCLC without actionable mutations: Is immunotherapy the panacea for all patients? BMC Med. , 16(1) : 24.
Lu D,Shen J,Vil MD,Zhang H,Jimenez X,Bohlen P .2003 .Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J. Biol. Chem, 278(44) : 43496-43507.
Park JO .2016 .Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis. Oncotarget., 7(46) : 75482-75491.
Qin S,Bai Y,Lim HY,Thongprasert S,Chao Y,Fan J .2013 .Randomized, multicenter, open-label trial of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J. Clin. Oncol., 31(28) : 3501-3508.
Rosell R and Crino L .2002 .Pemetrexed combination therapy in the treatment of non-small cell lung cancer. Semin Oncol., 29(2) : 23-29.
Shepherd FA .2001 .Phase II study of pemetrexed disodium, a multitargeted antifolate and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: A study of the National Cancer Institute of Canada Clinical Trials Group. , 92(3) : 595-600.
Siegel RL,Miller KD,Jemal A .2016 .. CA Cancer J. Clin., 66(1) : 7-30.
Torre LA,Bray F,Siegel RL,Ferlay J,Lortet-Tieulent J,Jemal A,Clin A .2012 .. Global cancer statistics, 65(2) : 87-108.
Wang Yongsheng .2012 .Erlotinib in the treatment of advanced non-small cell lung cancer: An update for clinicians. Ther. Adv. Med, 4(1) : 19-29.
Yoon HH,Bendell JC,Braiteh FS,Firdaus I,Philip PA .2016 .Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter phase II trial. , 27(12) : 2196-2203.
Zhu AX,Park JO,Ryoo BY,Yen CJ,Poon R,Pastorelli D R .2015 .Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial. , 16(7) : 859-870.
Zhu Z,Hattori K,Zhang H,Jimenez X,Ludwig DL,Dias S DL .2003 .Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia, 17(3) : 604-611.
0

Citations

0

Downloads

13

Views